Skip to Main Content

Rise and shine, everyone, a busy day is on the way. We can tell thanks to the shimmering sounds of the street outside our window and the number of mascots strolling by with their humans. As for us, we are preparing our to-do list and firing up the coffee kettle in order to enjoy another cup of stimulation. Our choice today is the aromatic wild mountain blueberry. As always, you are invited to join us. And why not? The neurons need as much help as they can get. Speaking of which, here are a few items of interest to help you jumpstart your morning. Hope all goes well today and you conquer the world. …

Worldwide demand for the Pfizer Covid-19 antiviral pill has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters review of data and interviews with experts has found. Demand also has been hampered by the perception that Omicron infections are not that severe. The pill, called Paxlovid, was expected to be a major tool in the fight against Covid-19 after it reduced hospitalizations or deaths in high-risk patients by around 90% in a clinical trial. But even amid a recent rise in infections, Paxlovid supply far outstripped demand in the United States, the U.K., Japan, and South Korea.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment